Please provide your email address to receive an email when new articles are posted on . Survival outcomes did not differ for patients with HNSCC who received radiotherapy with carboplatin-paclitaxel ...
Median overall survival (OS) and progression-free survival (PFS) in uterine carcinosarcoma (UCS) both improved with paclitaxel and carboplatin as compared with a standard-of-care regimen, a randomized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback